Miyagawa C I
Department of Pharmacy, University of Cincinnati College of Medicine, OH 45267-0740.
New Horiz. 1993 May;1(2):172-80.
Aminoglycosides have historically been the mainstay of antibiotic therapy in the ICU. Despite the availability of numerous less toxic antibiotics, the clinical and microbiologic attributes of these agents have ensured their continued use in the management of infections in the critically ill patient. Innovative dosing regimens may replace traditional dosing methods if they are shown to provide improved clinical response with less toxicity potential.
从历史上看，氨基糖苷类药物一直是重症监护病房抗生素治疗的主要药物。尽管有许多毒性较低的抗生素可供使用，但这些药物的临床和微生物学特性确保了它们在危重症患者感染管理中的持续应用。如果创新给药方案能显示出在降低潜在毒性的同时能提供更好的临床反应，那么它可能会取代传统给药方法。
